Al18F-PSMA-Q

Al18F-PSMA-Q is a novel radiopharmaceutical diagnostic agent designed for positron emission tomography (PET) imaging of prostate cancer. It consists of a PSMA-targeting ligand labeled with fluorine-18 using the aluminum-fluoride (Al18F) complexation method, which allows for a simplified, one-step radiolabeling process in aqueous media. The tracer specifically binds to the prostate-specific membrane antigen (PSMA), also known as glutamate carboxypeptidase II, which is highly overexpressed in prostate cancer cells and their metastases. Preclinical and pilot clinical studies have demonstrated that Al18F-PSMA-Q has high binding affinity, favorable pharmacokinetics with rapid clearance, and high tumor-to-background ratios, making it a promising tool for the detection and staging of primary prostate cancer and metastatic lesions.

Other names

[18F]AlF-PSMA-Qaluminum-18F-labeled PSMA-Qaluminum18F-labeled PSMA-Qaluminum 18F-labeled PSMA-Q